{"id":601,"date":"2016-06-11T11:04:08","date_gmt":"2016-06-11T16:04:08","guid":{"rendered":"https:\/\/3sixtypharma.com\/?p=601"},"modified":"2016-10-08T11:11:29","modified_gmt":"2016-10-08T16:11:29","slug":"pharma-spending-pd-1","status":"publish","type":"post","link":"https:\/\/3sixtypharma.com\/2016\/06\/11\/pharma-spending-pd-1\/","title":{"rendered":"$110B market: excessive spending on me-too PD-1 drugs?"},"content":{"rendered":"

\"science-news-pd-1\"<\/a><\/h1>\n

<\/h1>\n

Regulator says too many drugmakers chasing same cancer strategy<\/span><\/span><\/a><\/h1>\n

 <\/p>\n

Reuters reports that Dr. Richard Pazdur, who heads the Food and Drug Administration’s office of oncology products, believes that?too many companies are focused on PD-1 inhibitors for?cancer immunotherapy.<\/span><\/p>\n

Whereas PD-1 inhibitors show promise for remarkable efficacy, Dr. Pazdur is reportedly concerned that?too many companies are putting eggs in the same basket?taking the same risks?rather than investing in alternative novel therapies.<\/span><\/p>\n

“People should ask themselves … would we be better off spending those resources into looking at more novel drugs?” Pazdur reportedly told Reuters during the annual American Society of Clinical Oncology<\/a> (ASCO) meeting in Chicago.<\/span><\/p>\n

Bristol-Myers and Merck are widely viewed as leaders in the immunotherapy race, with treatments defying the odds to help patients fight off some of the deadliest cancers.??Read more…<\/a><\/span><\/span><\/p>\n

 <\/p>\n

Additional Reading<\/span><\/p>\n